NASDAQ · SXTC
China SXT Pharmaceuticals financials
$2.81+11.51%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Quarter | Q4 '26 Mar 31 | Q4 '25 Mar 31 | Q4 '24 Mar 31 | Q4 '23 Mar 31 | Q4 '22 Mar 31 | Q4 '21 Mar 31 | Q4 '20 Mar 31 | Q4 '19 Mar 31 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — | — | — |
| Gross margin | — | — | — | — | — | — | — | — |
| Operating income | — | — | — | — | — | — | — | — |
| Net income | — | — | — | — | — | — | — | — |
| Net margin | — | — | — | — | — | — | — | — |
| Diluted EPS | — | — | — | — | — | — | — | — |
| EBITDA | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Operating cash flow | — | — | — | — | — | — | — | — |
| Free cash flow | — | — | — | — | — | — | — | — |
| Diluted shares | 0.0M | 0.0M | 0.0M | 0.0M | 0.0M | 0.7M | 0.3M | 5.1M |
Balance sheet
| Period end | Mar 31 | Mar 31 | Mar 31 | Mar 31 | Mar 31 | Mar 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $28.2M | $18.1M | $12.1M | $17.4M | $15.5M | $13.3M |
| Short-term investments | $0.00 | $0.00 | $0.00 | $0.00 | — | — |
| Total debt | $999.6K | $807.2K | $2.4M | $3.5M | $11.4K | $43.4K |
| Total assets | $34.8M | $21.7M | $23.1M | $29.6M | $33.5M | $34.5M |
| Total liabilities | $5.0M | $6.2M | $9.2M | $14.9M | $17.1M | $18.6M |
| Shareholders' equity | $29.7M | $15.4M | $13.9M | $14.7M | $16.4M | $16.0M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology